{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=NASH+With+Fibrosis",
    "query": {
      "condition": "NASH With Fibrosis"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 84,
    "total_pages": 9,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=NASH+With+Fibrosis&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-06-10T22:15:01.078Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT03656068",
      "title": "An Evaluation of the Safety and Efficacy of Nitazoxanide on Collagen Turnover in NASH Patients With Fibrosis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Non-alcoholic Steatohepatitis",
        "Fatty Liver",
        "Fibrosis, Liver",
        "Compensated Cirrhosis"
      ],
      "interventions": [
        {
          "name": "Nitazoxanide 500mg BID",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pinnacle Clinical Research, PLLC",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 21,
      "start_date": "2018-12-04",
      "completion_date": "2020-11-25",
      "has_results": true,
      "last_update_posted_date": "2022-06-30",
      "last_synced_at": "2026-06-10T22:15:01.078Z",
      "location_count": 1,
      "location_summary": "San Antonio, Texas",
      "locations": [
        {
          "city": "San Antonio",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03656068"
    },
    {
      "nct_id": "NCT03449446",
      "title": "Study to Evaluate the Safety and Efficacy of Selonsertib, Firsocostat, Cilofexor, and Combinations in Participants With Bridging Fibrosis or Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis (NASH)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Nonalcoholic Steatohepatitis"
      ],
      "interventions": [
        {
          "name": "SEL",
          "type": "DRUG"
        },
        {
          "name": "FIR",
          "type": "DRUG"
        },
        {
          "name": "CILO",
          "type": "DRUG"
        },
        {
          "name": "Placebo to match FIR",
          "type": "DRUG"
        },
        {
          "name": "Placebo to match CILO",
          "type": "DRUG"
        },
        {
          "name": "Placebo to match SEL",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Gilead Sciences",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 395,
      "start_date": "2018-03-21",
      "completion_date": "2019-11-19",
      "has_results": true,
      "last_update_posted_date": "2020-12-03",
      "last_synced_at": "2026-06-10T22:15:01.078Z",
      "location_count": 81,
      "location_summary": "Chandler, Arizona • Phoenix, Arizona • Little Rock, Arkansas + 62 more",
      "locations": [
        {
          "city": "Chandler",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "North Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Chula Vista",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03449446"
    },
    {
      "nct_id": "NCT02686762",
      "title": "Emricasan, a Caspase Inhibitor, for Evaluation in Subjects With Non-Alcoholic Steatohepatitis (NASH) Fibrosis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Non-alcoholic Steatohepatitis",
        "Fibrosis",
        "Liver Diseases"
      ],
      "interventions": [
        {
          "name": "Emricasan (5 mg)",
          "type": "DRUG"
        },
        {
          "name": "Emricasan (50 mg)",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Conatus Pharmaceuticals Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 318,
      "start_date": "2016-01-26",
      "completion_date": "2019-02-28",
      "has_results": false,
      "last_update_posted_date": "2019-08-19",
      "last_synced_at": "2026-06-10T22:15:01.078Z",
      "location_count": 83,
      "location_summary": "Birmingham, Alabama • Tucson, Arizona • Little Rock, Arkansas + 63 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Freestone",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02686762"
    },
    {
      "nct_id": "NCT05463796",
      "title": "InAdvance: Surveillance, Prevention, and Interception in a Population at Risk for Cancer",
      "overall_status": "RECRUITING",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Cancer Risk",
        "Cancer Predisposition Syndrome",
        "Hereditary Cancer Prediction",
        "Childhood Cancer Survivors",
        "Adult Cancer Survivors",
        "IARC Carcinogens",
        "Smoking History",
        "Lung Cancer",
        "Ductal/Lobular Carcinoma",
        "Barrett Esophagus",
        "Pancreatic Precursor Lesions",
        "Colonic Dysplasia/Adenomata",
        "Non-Alcoholic Fatty Liver Disease",
        "Non Alcoholic Steatohepatitis",
        "Cirrhosis",
        "High Grade Prostatic Epithelial Neoplasia",
        "High-grade Bladder Urothelial Dysplasia/Carcinoma in Situ",
        "Adenomatous Hyperplasia",
        "High-risk Oral Precancerous Diseases",
        "Melanocytic Lesion, Adult",
        "Hematologic Malignancy",
        "Lung; Node",
        "Serous Tubal Intraepithelial Carcinoma",
        "Endometrial Intraepithelial Neoplasia",
        "Cervical and Endocervical Carcinoma in Situ",
        "Vulvar Intraepithelial Neoplasia",
        "Nephrogenic Rests",
        "Benign Bone Lesions With Risk of Malignant Degeneration",
        "Giant Cell Tumor",
        "Osteochondroma",
        "Spitz Nevus"
      ],
      "interventions": [
        {
          "name": "Samples",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "Dana-Farber Cancer Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 5000,
      "start_date": "2023-04-25",
      "completion_date": "2032-03-25",
      "has_results": false,
      "last_update_posted_date": "2025-08-07",
      "last_synced_at": "2026-06-10T22:15:01.078Z",
      "location_count": 1,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05463796"
    },
    {
      "nct_id": "NCT03486899",
      "title": "A Study of Experimental Medication BMS-986036 in Adults With Nonalcoholic Steatohepatitis (NASH) and Stage 3 Liver Fibrosis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Liver Fibrosis",
        "Nonalcoholic Fatty Liver Disease (NAFLD)",
        "Nonalcoholic Steatohepatitis"
      ],
      "interventions": [
        {
          "name": "BMS-986036",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Bristol-Myers Squibb",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 197,
      "start_date": "2018-06-19",
      "completion_date": "2021-08-17",
      "has_results": true,
      "last_update_posted_date": "2022-09-09",
      "last_synced_at": "2026-06-10T22:15:01.078Z",
      "location_count": 83,
      "location_summary": "Madison, Alabama • Chandler, Arizona • Phoenix, Arizona + 61 more",
      "locations": [
        {
          "city": "Madison",
          "state": "Alabama"
        },
        {
          "city": "Chandler",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03486899"
    },
    {
      "nct_id": "NCT03486912",
      "title": "A Study of Experimental Medication BMS-986036 in Adults With Nonalcoholic Steatohepatitis (NASH) and Liver Cirrhosis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Hepatic Cirrhosis",
        "Liver Fibrosis",
        "Nonalcoholic Fatty Liver Disease (NAFLD)",
        "Nonalcoholic Steatohepatitis"
      ],
      "interventions": [
        {
          "name": "BMS-986036",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Bristol-Myers Squibb",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 155,
      "start_date": "2018-06-12",
      "completion_date": "2021-09-14",
      "has_results": true,
      "last_update_posted_date": "2022-10-13",
      "last_synced_at": "2026-06-10T22:15:01.078Z",
      "location_count": 85,
      "location_summary": "Madison, Alabama • Chandler, Arizona • Phoenix, Arizona + 62 more",
      "locations": [
        {
          "city": "Madison",
          "state": "Alabama"
        },
        {
          "city": "Chandler",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03486912"
    },
    {
      "nct_id": "NCT05835180",
      "title": "A Phase I Pharmacokinetic Study of TVB-2640 (Denifanstat) in Subjects With Mild, Moderate, or Severe Hepatic Impairment Compared to Subjects With Normal Hepatic Function",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Non-alcoholic Steatohepatitis",
        "Hepatic Impairment",
        "Cirrhosis"
      ],
      "interventions": [
        {
          "name": "TVB-2640 - 50 mg",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Sagimet Biosciences Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 48,
      "start_date": "2023-05-01",
      "completion_date": "2023-12-18",
      "has_results": false,
      "last_update_posted_date": "2023-12-26",
      "last_synced_at": "2026-06-10T22:15:01.078Z",
      "location_count": 2,
      "location_summary": "Orlando, Florida • San Antonio, Texas",
      "locations": [
        {
          "city": "Orlando",
          "state": "Florida"
        },
        {
          "city": "San Antonio",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05835180"
    },
    {
      "nct_id": "NCT02462967",
      "title": "Clinical Trial to Evaluation the Safety and Efficacy of GR-MD-02 for the Treatment of Liver Fibrosis and Resultant Portal Hypertension in Patients With Nash Cirrhosis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Hypertension, Portal"
      ],
      "interventions": [
        {
          "name": "GR-MD-02",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Galectin Therapeutics Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 162,
      "start_date": "2015-06",
      "completion_date": "2017-10",
      "has_results": true,
      "last_update_posted_date": "2020-10-08",
      "last_synced_at": "2026-06-10T22:15:01.078Z",
      "location_count": 46,
      "location_summary": "Los Angeles, California • Sacramento, California • San Diego, California + 39 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Gainesville",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02462967"
    },
    {
      "nct_id": "NCT04849728",
      "title": "A Phase 3 Study Evaluating Efficacy and Safety of Lanifibranor Followed by an Active Treatment Extension in Adult Patients With (NASH) and Fibrosis Stages F2 and F3 ( NATiV3 )",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "NASH - Nonalcoholic Steatohepatitis"
      ],
      "interventions": [
        {
          "name": "IVA337",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Inventiva Pharma",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 1000,
      "start_date": "2021-08-19",
      "completion_date": "2027-09-30",
      "has_results": false,
      "last_update_posted_date": "2026-05-20",
      "last_synced_at": "2026-06-10T22:15:01.078Z",
      "location_count": 194,
      "location_summary": "Birmingham, Alabama • Dothan, Alabama • Madison, Alabama + 142 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Dothan",
          "state": "Alabama"
        },
        {
          "city": "Madison",
          "state": "Alabama"
        },
        {
          "city": "Chandler",
          "state": "Arizona"
        },
        {
          "city": "Peoria",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04849728"
    },
    {
      "nct_id": "NCT05809934",
      "title": "A Study to Evaluate AZD2693 in Participants Who Are Carriers of the PNPLA3 148M Risk Allele With Non-cirrhotic Non-alcoholic Steatohepatitis With Fibrosis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Nonalcoholic Steatohepatitis"
      ],
      "interventions": [
        {
          "name": "AZD2693",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "AstraZeneca",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 220,
      "start_date": "2023-03-15",
      "completion_date": "2025-09-29",
      "has_results": false,
      "last_update_posted_date": "2025-10-28",
      "last_synced_at": "2026-06-10T22:15:01.078Z",
      "location_count": 37,
      "location_summary": "Chandler, Arizona • Peoria, Arizona • Surprise, Arizona + 33 more",
      "locations": [
        {
          "city": "Chandler",
          "state": "Arizona"
        },
        {
          "city": "Peoria",
          "state": "Arizona"
        },
        {
          "city": "Surprise",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05809934"
    }
  ]
}